Developing a fully validated lateral flow assay is a multi-step process that can take 6 to 24 months depending on the complexity of the assay, availability of reagents and samples, performance requirements, and regulatory pathway. The development cycle typically progresses from early feasibility through assay development, verification, validation, and transfer to manufacturing.
Previous: Introduction to Lateral Flow Assays
Developing a nanoparticle-based diagnostic?
Explore nanoparticle reporter options, selection guidance, and development support for diagnostic applications.
The Lateral Flow Assay Development Cycle
Phase I: Feasibility
Before allocating significant resources to assay development, the first step is to determine whether the intended test is scientifically and financially feasible. The process begins by defining initial product specifications, including what you are trying to detect (target analyte), where you are detecting it (sample matrix), and how the test will ultimately be used (intended use). These specifications narrow the scope of the project and provide measurable targets for feasibility testing.
Feasibility work also requires evaluating the availability of critical reagents, reporter particles, and representative samples. If suitable antibodies or other affinity reagents are not commercially available, custom development may be required. Likewise, the availability, cost, lead time, and scalability of the reporter nanoparticle should be considered early because these factors can influence both technical feasibility and the eventual commercial assay.
If an off-the-shelf nanoparticle does not meet the required performance or integration needs, our custom nanoparticle and custom conjugation development programs can support early feasibility studies and evaluation of specialized particle designs.
Representative samples are also important during feasibility testing. Clinical and other biological samples can be costly and time-consuming to obtain, so the sample strategy should be considered during project planning. The number and type of samples required will depend on the study objective, analyte, intended use, and applicable statistical or regulatory guidance.
If the assay demonstrates sufficient technical and commercial feasibility, development can proceed to systematic optimization.
Phase II: Assay Development
During assay development, the initial concept is translated into a defined test system. Early scoping establishes the development activities, quality requirements, expected timeline, and considerations for eventual transfer to manufacturing. More detailed design requirements are also established to define the performance the assay must achieve.
Assay optimization typically accounts for much of the work during this phase. Variables can include antibody pairs, reporter nanoparticles, conjugation conditions, membrane and pad materials, reagent concentrations, flow characteristics, sample preparation, cassette design, and reader requirements. The end goal is a well-defined assay design that can be consistently reproduced and advanced toward design freeze.
For physical strip optimization, our Material Starter Kit for Lateral Flow provides multiple nitrocellulose membranes, conjugate pads, sample pads, wick pads, and other materials for comparative screening.
Phase III: Assay Verification
Verification evaluates whether the developed assay meets the design requirements established earlier in the program. Engineering lots can be used to characterize analytical performance and demonstrate that the design outputs satisfy the defined specifications.
Depending on the assay, verification activities may include evaluation of limit of detection, analytical range, precision, specificity, interference, reproducibility, and other defined performance characteristics. Manufacturing processes and draft batch records are also refined as the assay moves toward a controlled production process.
Phase IV: Validation & Transfer to Manufacturing
Validation evaluates whether the final assay performs as intended for its specified use and users. The scope of validation will depend on the product, intended use, and applicable regulatory pathway.
In parallel, manufacturing procedures, specifications, quality controls, and batch records are finalized for transfer into production. Validation or production-equivalent lots may then be used for more comprehensive performance studies and, where applicable, to support regulatory submissions.
For diagnostic programs that require scalable nanoparticle conjugates, nanoComposix can also support custom conjugate development and manufacturing from early optimization through larger-scale production.
Design Requirements Guide the Entire Development Cycle
Each phase depends on having clear, measurable targets for what the assay needs to accomplish. Establishing those requirements early provides a framework for feasibility studies, optimization decisions, verification testing, and eventual validation.
The next step is to define the design requirements that will guide development and establish the metrics your assay needs to achieve.
Next: Define the assay design requirements